Clinical stage European muscle recovery company for sale

Company for sale

• Size: medium
• Revenue: n/a.
• Established: 2009
• Stake for sale: 100%
• Location of this pharma manufacturer: Western Europe
• #CFIE PHS022

Overview of this clinical stage European muscle recovery booster drug laboratory

This company for sale is a privately owned Bio-pharmaceutical company that focuses on the development of medicines that restore muscle strength and mitigate muscular atrophy in older patients.

Profile of this clinical stage muscle recovery booster drug laboratory

From the start more than 10 years ago, the company succeeded in reaching significant milestones in developing their first product and in protecting the technology through patents. The PCT patent application has been converted in patent applications in all attractive countries both from a market and strategic perspective. The R&D strategy of O1 allows at filling the pipeline with Recovery Boosters for new therapeutic indications for male and female patients under the first patent and for a patent umbrella strategy.

Products and services of this clinical stage muscle recovery booster company

The company developed a unique patented recovery booster therapy NDD (Nandrolone-Decanoate and vitamin D); a new class of prescription drugs that support the recovery process after hip fracture surgery by mitigation of the disuse atrophy and activation of satellite cells, also known as muscle stem cells. The proposed mechanism by which NDD affects muscle cells in vitamin D deficient older patients, results in an effective and safe short-term pharmacotherapy that supports the postoperative recovery of the older patients, thereby lowering the side effects and complications.

Highlights of clinical stage muscle recovery booster company

• The market potential for this drug is $4.8 billion the USA, EU-5 and Japan
• Preliminary market research suggests high penetration potential in the Chinese market also, if first to market
• The NDD clinical drug candidate addresses a large, unmet need with significant growth supported by demographic trends
• NDD has a great reimbursement profile from payors, as its use results in a highly desirable outcome of lower hospitalization costs and faster functional recovery of older patients
• High probability of regulatory approval, based on NDD being a novel combination of existing approved drugs with a safe, short-term pharmacotherapy for this therapeutic indication on orthopedic patients
• For all IP, pre-clinical data, including clinical plans to start Phase 2 and knowledge, the asking price is € 60 million euro (negotiable)

More information on this clinical stage European muscle recovery company for sale

Please get in touch if you are interested in learning more about this clinical stage European muscle recovery company for sale. For more cro companies for sale please visit the section cro companies for sale. For other cro buyers, please visit the section cro companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.